✦ LIBER ✦

Imaging end points for monitoring neuroprotection in Parkinson's disease

✍ Scribed by David J. Brooks

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 312 KB
Volume: 53
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.10480

No coin nor oath required. For personal study only.

✦ Synopsis

In this review, the potential role of positron emission tomography and single-photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD.

📜 SIMILAR VOLUMES

Bioenergetic approaches for neuroprotect

Bioenergetic approaches for neuroprotection in Parkinson's disease

✍ M. Flint Beal 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

Rationale for the use of dopamine agonis

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

✍ Anthony H. V. Schapira; C. Warren Olanow 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

Altropane, a SPECT or PET imaging probe

Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain

✍ Bertha K. Madras; Lawrence M. Gracz; Michele A. Fahey; David Elmaleh; Peter C. M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Increasing evidence suggests that the dopamine transporter is situated almost exclusively on dopamine neurons. Accordingly, it is an valuable marker for Parkinson's disease and other pathological states of dopamine neurons. We previously demonstrated that the potent dopamine transport inhibitor [ 12